Patient characteristics
| Characteristic | n=186 |
| Median age, years (range) | 59.5 (26–87) |
| Cancer type, n (%) | |
| Colorectal | 55 (30%) |
| Ovarian | 52 (28%) |
| Breast | 22 (12%) |
| Pancreatic | 16 (9%) |
| Endometrial | 14 (8%) |
| Upper gastrointestinal tract* | 12 (6%) |
| Other† | 11 (6%) |
| Unknown primary | 4 (2%) |
| Antineoplastic drug, n (%) | |
| Platinum | |
| Oxaliplatin | 83 (45%) |
| Carboplatin | 64 (34%) |
| Cisplatin | 8 (4%) |
| Taxane | |
| Docetaxel | 8 (4%) |
| Paclitaxel | 8 (4%) |
| Liposomal doxorubicin | 9 (5%) |
| Trastuzumab | 6 (3%) |
| Median number of other drug allergies, n (range) | 1 (0–11) |
| Median number of prior cycles containing drug for desensitization, n (range) | 7.5 (0–40) |
*Upper gastrointestinal tract cancers include bile duct, esophageal, gallbladder, gastric, and hepatocellular cancers.
†Other cancers include lung, lymphoma, mesothelioma, parotid gland, and prostate cancers.